IRIS

Sfoglia per Autore  JOMMI, CLAUDIO

Opzioni
Mostrati risultati da 1 a 20 di 175
Titolo Data di pubblicazione Autore(i) File
How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy? 1-gen-2023 Drummond, Michael; Ciani, Oriana; Fornaro, Giulia; Jommi, Claudio; Dietrich, Eva Susanne; Espin, Jaime; Mossman, Jean; de Pouvourville, Gerard
Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access 1-gen-2023 Giovannelli, Lorella; Bari, Elia; Jommi, Claudio; Tartara, Fulvio; Armocida, Daniele; Garbossa, Diego; Cofano, Fabio; Torre, Maria Luisa; Segale, Lorena
Early access programs for medicines: comparative analysis among France, Italy, Spain, and UK and focus on the Italian case 1-gen-2023 Tarantola, A.; Otto, M. H.; Armeni, P.; Costa, F.; Malandrini, F.; Jommi, C.
The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency 1-gen-2023 Jommi, Claudio; Galeone, Carlotta
EQ-5D-5L Population Norms for Italy 1-gen-2023 Meregaglia, Michela; Malandrini, Francesco; Finch, Aureliano Paolo; Ciani, Oriana; Jommi, Claudio
Do France, Germany, and Italy agree on the added therapeutic value of medicines? 1-gen-2023 Casilli, Giorgio; Lidonnici, Dario; Jommi, Claudio; De Nigris, Marika; Genazzani, Armando
An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration 1-gen-2022 Finch, Aureliano Paolo; Meregaglia, Michela; Ciani, Oriana; Roudijk, Bram; Jommi, Claudio
Faciliating More Efficient Negotiations for Innovative Therapies: A Value-Based Negotiation Framework 1-gen-2022 Whittal, A.; Jommi, C.; De Pouvourville, G.; Taylor, D.; Annemans, L.; Schoonaert, L.; Vermeersch, S.; Hutchings, A.; Patris, J.
Unmet clinical need and new therapeutic options 1-gen-2022 Caprari, F.; Alfano, A.; Buzzetti, G.; Consoli, A.; De Braud, F.; Patarnello, F.; Pitrelli, A.; Riccaboni, M.; Rossi, G.; Samele, R.; Scaduto, D.; Viale, P.; Jommi, C.; Popoli, P.
CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions 1-gen-2022 Jommi, C.; Bramanti, S.; Pani, M.; Ghirardini, A.; Santoro, A.
The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study 1-gen-2022 Bertolani, A; Ravasio, R; Raimondo, P; Jommi, C
The future of Funds for Innovative Medicines: results from a Delphi Study 1-gen-2021 Jommi, Claudio; Armeni, Patrizio; Bertolani, Arianna; Costa, Francesco; Otto, Monica
The economic impact of compassionate use of medicines 1-gen-2021 Jommi, Claudio; Pantellini, Federico; Stagi, Lisa; Verykiou, Maria; Cavazza, Marianna
Early access programs and managed entry agreements for medicines in Italy: Results of a Focus Group (Early Access Programs and Managed Entry Agreement) 1-gen-2021 Jommi, C.; Armeni, P.; Costa, F.; Alberti, C.; Bandello, F.; Bordonaro, R.; Caprodossi, A.; Di Maio, M.; Gaudioso, A.; Giuliani, G.; Langella, R.; Marata, A. M.; Patarnello, F.; Pinto, C.; Rasi, G.; Villa, F.
Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital 1-gen-2021 Chiumente, Marco; Russi, Alberto; Todino, Federica; Mengato, Daniele; Coppola, Marina; Rivano, Melania; Palozzo, Angelo C.; Jommi, Claudio
Variables affecting pricing of orphan drugs: the Italian case 1-gen-2021 Jommi, Claudio; Listorti, Elisabetta; Villa, Federico; Ghislandi, Simone; Genazzani, Armando; Cangini, Agnese; Trotta, Francesco
Price and reimbursement of advanced therapeutic medicinal products in Europe: are assessment and appraisal diverging from expert recommendations? 1-gen-2021 Ronco, V.; Dilecce, M.; Lanati, E.; Canonico, P. L.; Jommi, C.
Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects 1-gen-2021 Rognoni, C.; Bertolani, A.; Jommi, C.
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system 1-gen-2021 Riva, S.; Arenare, L.; Di Maio, M.; Efficace, F.; Montesarchio, V.; Frontini, L.; Giannarelli, D.; Bryce, J.; Del Campo, L.; De Lorenzo, F.; Iannelli, E.; Traclo, F.; Gitto, L.; Jommi, C.; Vaccaro, C. M.; Barberio, D.; Cinieri, S.; Porta, C.; Del Mastro, L.; Zagonel, V.; Cogoni, A. A.; Bordonaro, R.; Gimigliano, A.; Piccirillo, M. C.; Guizzaro, L.; Gallo, C.; Perrone, F.
A qualitative analysis and development of a conceptual model assessing financial toxicity in cancer patients accessing the universal healthcare system 1-gen-2021 Riva, S.; Efficace, F.; Di Maio, M.; Bryce, J.; Del Campo, L.; De Lorenzo, F.; Frontini, L.; Giannarelli, D.; Gitto, L.; Iannelli, E.; Jommi, C.; Montesarchio, V.; Traclo, F.; Vaccaro, C. M.; Arenare, L.; Canzanella, G.; Gimigliano, A.; Romano, F.; Savio, A.; Sparavigna, L.; Piccirillo, M. C.; Guizzaro, L.; Gallo, C.; Perrone, F.
Mostrati risultati da 1 a 20 di 175
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile